050 – Acasti Pharma’s Novel Omega-3 Formulation Steps Up!

Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. We discuss the omega-3 space and Acasti’s EPA/DHA formulation called CaPre. Acasti is seeking the approval of CaPre for the indication of severe hypertriglyceridemia and has two pivotal catalysts at the end of the year, which will be massive movers for the stock. Amarin’s upcoming catalysts are also likely to affect them. Check out the whole video for more details!

Relevant links:
https://www.acastipharma.com/en/investors/company-information/presentations
https://www.aegiscapcorp.com/service/nathan-weinstein/

this is not investment advice

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s